Latest research on Lucentis

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

Latest findings

At 12 months, 94.5% of 0.3 mg of ranibizumab and 94.6% of 0.5 mg of ranibizumab lost fewer than 15 letters compared to 62.2% in controls for minimally classic or occult lesions;11 33.8% of 0.5 mg Lucentis gained ≥ 15 letters and 24.8% in the 0.3 mg group which was maintained till 24 months. [source, 2007]
When compared with Verteporfin, 94.3% of patients receiving 0.3 mg of Lucentis and 96.4% patients in the 0.5 mg group lost fewer than 15 letters compared to 64.3% in the Verteporfin-treated group at 24 months for classic lesions. [source, 2007]
In a study of ranibizumab (Lucentis) in people with minimally classic or occult MD, treatment groups showed significant improvements in NEI-VFQ scores (near and distance activities and dependency) over one year compared with controls [141]. [source, 2006]
Currently available and approved treatments for neovascular AMD include: focal thermal laser; photodynamic therapy with Verteporfin (Visudyne, QLT Photo-therapeutics, Inc., Vancouver, British Columbia); and targeted anti-VEGF treatment with pegaptanib (Macugen, Eyetech Pharmaceuticals, New York, NY) and the recently US Food and Drug Administration-approved ranibizumab (rhuFab V2, Lucentis, Genentech, Inc., South San Francisco, CA). [source, 2006]
Ranibizumab (rhuFab V2, Lucentis, Genentech, Inc., South San Francisco, CA) is a 48 kDA, recombinant, humanized, monoclonal antibody fragment (Fab portion) derivative of bevacizumab with specificity to all isoforms of VEGF and is designed to inhibit angiogenesis and reduce vascular permeability in neovascular AMD. [source, 2006]
The MARINA (Minimally classic/occult trial of Anti-VEGF antibody rhuFab V2 In the treatment of Neovascular AMD) Trial prospectively randomized 716 patients 1:1:1 to receive monthly intravitreal ranibizumab (300μg or 500μg) or sham injections for 24 months. [source, 2006]
A smaller phase I/II study, FOCUS (rhuFab V2 Ocular Treatment Combining the Use of Visudyne to Evaluate Safety), studied the efficacy of monthly intravitreal ranibizumab (500μg) in combination with PDT compared with PDT only in 162 patients with predominantly classic CNV (Heier et al 2006). [source, 2006]
Another small, open-label phase I/II study, PrONTO (Prospective OCT Imaging of Patients with Neovascular AMD with Intra-Ocular Lucentis), has studied a variable dosing regimen for intravitreal ranibizumab in neovascular AMD of any lesion type. [source, 2006]